Company Profile
Cingulate Inc. Stock Price, News & Analysis
- Ticker:
- CING
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.05 USD (+2.23%)
Close
Last updated: August 6, 2026
54.3M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CING closed up 2.23% at $5.05. No new same-company headline was identified in the current news window.
Company overview
Precision Timed Release Platform
Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence.
CTx-1301 ADHD Candidate
CTx-1301 is a once-daily, multi-core dexmethylphenidate hydrochloride tablet for attention-deficit/hyperactivity disorder. It is designed to provide rapid onset and efficacy throughout the active day and is being reviewed through the FDA’s 505(b)(2) pathway.
505(b)(2) Development Model
The regulatory strategy uses an established active pharmaceutical ingredient while seeking approval for a differentiated release profile and dosage form. This allows Cingulate to focus development on pharmacokinetics, duration of effect, manufacturing, and product-specific clinical performance.
Commercial Readiness
Cingulate is preparing payer access, distribution, supply chain, artificial intelligence-supported marketing technology, commercial manufacturing, and a sales organization for CTx-1301. Launch remains dependent on FDA approval.
Future catalysts
The FDA accepted the CTx-1301 NDA and assigned a PDUFA target action date of May 31, 2026.
Cingulate is responding to FDA information requests related to manufacturing and CMC, with the outcome of the review determining potential approval and launch readiness.
Recent news
- 01
- 02
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Source: Cingulate Inc.
- 03
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Source: Cingulate Inc.
- 04
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Source: Cingulate Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cingulate Inc. (CING)?
Cingulate Inc. (CING) most recently closed at 5.05 USD, a +2.23% move versus the previous session.
What is the market cap of Cingulate Inc. (CING)?
Cingulate Inc. currently has a market capitalization of 54.3M USD on BioPharmSignal.
What does Cingulate Inc. do?
Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence. CTx-1301 ADHD Candidate CTx-1301 is a once-daily, multi-core...
On which exchange is CING stock listed?
Cingulate Inc. (CING) is associated with NASDAQ, United States, Biopharma.
What is Precision?
Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform.
Which conditions is Cingulate Inc. targeting with Precision?
Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence. CTx-1301 ADHD Candidate CTx-1301 is a once-daily, multi-core...
How does Cingulate Inc. describe recent progress with Precision?
The FDA accepted the CTx-1301 NDA and assigned a PDUFA target action date of May 31, 2026. Cingulate is responding to FDA information requests related to manufacturing and CMC, with the outcome of the review determining potential approval and launch readiness.
What is Timed?
Precision Timed Release Platform Cingulate develops next-generation medicines using its Precision Timed Release platform.